Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00344292 · ClinicalTrials.gov registry record

Understanding the Genetic and Hereditary Basis of Atherosclerosis

A clinical trial of Cardiovascular Diseases and Atherosclerosis, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
2,763
Enrollment target
4
Study locations

NCT00344292 is a study of Cardiovascular Diseases and Atherosclerosis that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 2,763 participants, below the 26,965-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00344292, a study of Cardiovascular Diseases and Atherosclerosis, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
2,763 participants
Enrollment target
4
Study locations

Study Summary

Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible for the development of atherosclerosis.

Study Locations (4)

California

  • Cedars-Sinai Health System - Los Angeles

Louisiana

  • Louisiana State University - New Orleans

Texas

  • The University of Texas - Houston

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 2,763 participants
Start Date 2006-03
Est. Completion 2012-02

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT00344292

The ClinicalTrials.gov registry entry for NCT00344292 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,763 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,965-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (90% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT00344292 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Louisiana, Texas.

Frequently Asked Questions

What is clinical trial NCT00344292 about?

NCT00344292 is a clinical study titled "Understanding the Genetic and Hereditary Basis of Atherosclerosis". Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible...

What is the current status of trial NCT00344292?

This trial is currently completed. The enrollment target is 2,763 participants. The study started on 2006-03. Estimated completion is 2012-02.

What conditions does trial NCT00344292 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Atherosclerosis.

Who is sponsoring clinical trial NCT00344292?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00344292 being conducted?

This trial has 4 study locations across California, Louisiana, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.